trending Market Intelligence /marketintelligence/en/news-insights/trending/jK_ereZ9P75EzRBqgS9c3g2 content esgSubNav
In This List

US FDA grants fast track designation to Radius Health's breast cancer drug

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


US FDA grants fast track designation to Radius Health's breast cancer drug

The U.S. Food and Drug Administration granted fast-track designation to Radius Health Inc.'s breast cancer drug estrogen.

The company said the drug is being evaluated in two ongoing phase 1 studies and will be evaluated in a phase 2 study in early 2018.